US House Subpanel Would Give FDA Device Center An 8.5% Raise In 2020

A House subpanel overseeing US FDA spending approved an 8.5% boost – $33 million additional – in the agency’s device center funding for 2020, over 2019 levels. 

FDAEntrance_1200x675
US FDA’s device center would get a significant boost in funding in 2020 under a new House Appropriations Committee, subpanel bill

If a House appropriations subcommittee has its say, theUS Food and Drug Administration’s device center would receive $420m in congressional budget authority in fiscal year 2020 – a raise of 8.5% over the current year’s spending level of $387m. The bill was approved on May 23 by an agriculture and FDA subpanel of the House Committee on Appropriations.

The addition of $219.5m in device user fees slated for 2020, plus the proposed $33m raise, means that device center personnel at FDA would have approximately $606.5m total to review...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.